Maternal genotype determines kynurenic acid levels in the fetal brain: Implications for the pathophysiology of schizophrenia

Journal of Psychopharmacology

Volumn 32, Issue 11, 2018, Pages 1223-1232

  Beggiato, Sarah ^a   Notarangelo, Francesca M ^b   Sathyasaikumar, Korrapati V ^b   Giorgini, Flaviano ^c   Schwarcz, Robert ^b  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Cognition; development; kynurenine 3 monooxygenase; prenatal; tryptophan

Indexed keywords

3 HYDROXYKYNURENINE; KYNURENIC ACID; QUINOLINIC ACID; 3-HYDROXYKYNURENINE; KYNURENINE; KYNURENINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; DISEASE COURSE; EMBRYO; EMBRYO TISSUE; FEMALE; FETUS; FETUS BRAIN; GENOTYPE; GESTATION PERIOD; HETEROZYGOTE; MALE; MATERNAL BLOOD; METABOLIC PARAMETERS; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PLACENTA TISSUE; PRIORITY JOURNAL; PROGENY; QUALITATIVE ANALYSIS; SCHIZOPHRENIA; WILD TYPE; ANIMAL; BRAIN; C57BL MOUSE; COGNITIVE DEFECT; GENETICS; KNOCKOUT MOUSE; METABOLISM; PLACENTA; PREGNANCY;

ANIMALS; BRAIN; COGNITIVE DYSFUNCTION; FEMALE; GENOTYPE; KYNURENIC ACID; KYNURENINE; KYNURENINE 3-MONOOXYGENASE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PLACENTA; PREGNANCY; QUINOLINIC ACID; SCHIZOPHRENIA;

EID: 85056277678     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881118805492     Document Type: Article

References (70)

1. Abazyan B, Nomura J, Kannan G. (2010) Prenatal interaction of mutant DISC1 and immune activation produces adult psychopathology. Biol Psychiatry 68: 1172–1181
2. Akagbosu CO, Evans GC, Gulick D. (2012) Exposure to kynurenic acid during adolescence produces memory deficits in adulthood. Schizophr Bull 38: 769–778
3. Alberati-Giani D, Cesura AM, Broger C. (1997) Cloning and functional expression of human kynurenine 3-monooxygenase. FEBS Lett 410: 407–412
4. Alexander KS, Wu HQ, Schwarcz R. (2012) Acute elevations of brain kynurenic acid impair cognitive flexibility: Normalization by the alpha7 positive modulator galantamine. Psychopharmacology (Berl) 220: 627–637
5. Aoyama N, Takahashi N, Saito S. (2006) Association study between kynurenine 3-monooxygenase gene and schizophrenia in the Japanese population. Genes Brain Behav 5: 364–368
6. Arnedo J, Svrakic DM, Del Val C. (2015) Uncovering the hidden risk architecture of the schizophrenias: Confirmation in three independent genome-wide association studies. Am J Psychiatry 172: 139–153
7. Beal MF, Swartz KJ, Isacson O, (1992) Developmental changes in brain kynurenic acid concentrations. Brain Res Dev Brain Res 68: 136–139
8. Ben-Ari Y, Khazipov R, Leinekugel X. (1997) GABAA, NMDA and AMPA receptors: A developmentally regulated ‘menage a trois’. Trends Neurosci 20: 523–529
9. Brown AS, Vinogradov S, Kremen WS. (2009) Prenatal exposure to maternal infection and executive dysfunction in adult schizophrenia. Am J Psychiatry 166: 683–690
10. Cannazza G, Chiarugi A, Parenti C. (2001) Changes in kynurenic, anthranilic, and quinolinic acid concentrations in rat brain tissue during development. Neurochem Res 26: 511–514
11. Carpenedo R, Chiarugi A, Russi P. (1994) Inhibitors of kynurenine hydroxylase and kynureninase increase cerebral formation of kynurenate and have sedative and anticonvulsant activities. Neuroscience 61: 237–243
12. Carpenter WT, Buchanan RW, Jr (1994) Schizophrenia. N Engl J Med 330: 681–690
13. Ceresoli-Borroni G, Rassoulpour A, Wu HQ. (2006) Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain. J Neural Transm (Vienna) 113: 1355–1365
14. Chess AC, Bucci DJ, (2006) Increased concentration of cerebral kynurenic acid alters stimulus processing and conditioned responding. Behav Brain Res 170: 326–332
15. Chess AC, Simoni MK, Alling TE. (2007) Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophr Bull 33: 797–804
16. Dalal SJ, Estep JS, Valentin-Bon IE. (2001) Standardization of the Whitten Effect to induce susceptibility to Neisseria gonorrhoeae in female mice. Contemp Top Lab Anim Sci 40: 13–17
17. DeAngeli NE, Todd TP, Chang SE. (2014) Exposure to kynurenic acid during adolescence increases sign-tracking and impairs long-term potentiation in adulthood. Front Behav Neurosci 8: 451
18. Debnath M, Venkatasubramanian G, Berk M, (2015) Fetal programming of schizophrenia: Select mechanisms. Neurosci Biobehav Rev 49: 90–104
19. Dwyer JB, McQuown SC, Leslie FM, (2009) The dynamic effects of nicotine on the developing brain. Pharmacol Ther 122: 125–139
20. Eastman CL, Guilarte TR, Lever JR, (1992) Uptake of 3-hydroxykynurenine measured in rat brain slices and in a neuronal cell line. Brain Res 584: 110–116
21. Erhardt S, Blennow K, Nordin C. (2001) Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett 313: 96–98
22. Erhardt S, Pocivavsek A, Repici M. (2017) Adaptive and behavioral changes in kynurenine 3-monooxygenase knockout mice: Relevance to psychotic disorders. Biol Psychiatry 82: 756–765
23. Erhardt S, Schwieler L, Emanuelsson C. (2004) Endogenous kynurenic acid disrupts prepulse inhibition. Biol Psychiatry 56: 255–260
24. Estes ML, McAllister AK, (2016) Maternal immune activation: Implications for neuropsychiatric disorders. Science 353: 772–777
25. Flores-Barrera E, Thomases DR, Cass DK. (2017) Preferential disruption of prefrontal GABAergic function by nanomolar concentrations of the alpha7nACh negative modulator kynurenic acid. J Neurosci 37: 7921–7929
26. Forrest CM, Khalil OS, Pisar M. (2013a) Prenatal inhibition of the tryptophan-kynurenine pathway alters synaptic plasticity and protein expression in the rat hippocampus. Brain Res 1504: 1–15
27. Forrest CM, Khalil OS, Pisar M. (2013b) Changes in synaptic transmission and protein expression in the brains of adult offspring after prenatal inhibition of the kynurenine pathway. Neuroscience 254: 241–259
28. Fukui S, Schwarcz R, Rapoport SI. (1991) Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem 56: 2007–2017
29. Giorgini F, Huang SY, Sathyasaikumar KV. (2013) Targeted deletion of kynurenine 3-monooxygenase in mice: A new tool for studying kynurenine pathway metabolism in periphery and brain. J Biol Chem 288: 36554–36566
30. Gleason G, Zupan B, Toth M, (2011) Maternal genetic mutations as gestational and early life influences in producing psychiatric disease-like phenotypes in mice. Front Psychiatry 2: 25
31. Holtze M, Saetre P, Engberg G. (2012) Kynurenine 3-monooxygenase polymorphisms: Relevance for kynurenic acid synthesis in patients with schizophrenia and healthy controls. J Psychiatry Neurosci 37: 53–57
32. Khalil OS, Pisar M, Forrest CM. (2014) Prenatal inhibition of the kynurenine pathway leads to structural changes in the hippocampus of adult rat offspring. Eur J Neurosci 39: 1558–1571
33. Kirkbride JB, Susser E, Kundakovic M. (2012) Prenatal nutrition, epigenetics and schizophrenia risk: Can we test causal effects? Epigenomics 4: 303–315
34. Larsson MK, Faka A, Bhat M. (2016) Repeated LPS injection induces distinct changes in the kynurenine pathway in mice. Neurochem Res 41: 2243–2255
35. Ligam P, Manuelpillai U, Wallace EM. (2005) Localisation of indoleamine 2,3-dioxygenase and kynurenine hydroxylase in the human placenta and decidua: Implications for role of the kynurenine pathway in pregnancy. Placenta 26: 498–504
36. Linderholm KR, Skogh E, Olsson SK. (2012) Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bull 38: 426–432
37. Lowry OH, Rosebrough NJ, Farr AL. (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265–275
38. Manuelpillai U, Ligam P, Smythe G. (2005) Identification of kynurenine pathway enzyme mRNAs and metabolites in human placenta: Up-regulation by inflammatory stimuli and with clinical infection. Am J Obstet Gynecol 192: 280–288
39. Martin J, Tilling K, Hubbard L. (2016) Association of genetic risk for schizophrenia with nonparticipation over time in a population-based cohort study. Am J Epidemiol 183: 1149–1158
40. Meyer U, (2014) Prenatal poly(i:C) exposure and other developmental immune activation models in rodent systems. Biol Psychiatry 75: 307–315
41. Misiak B, Stramecki F, Gaweda L. (2018) Interactions between variation in candidate genes and environmental factors in the etiology of schizophrenia and bipolar disorder: A systematic review. Mol Neurobiol 55: 5075–5100
42. Mittal VA, Ellman LM, Cannon TD, (2008) Gene-environment interaction and covariation in schizophrenia: The role of obstetric complications. Schizophr Bull 34: 1083–1094
43. Müller N, Schwarz M, (2006) Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotox Res 10: 131–148
44. Notarangelo FM, Schwarcz R, (2016) Restraint stress during pregnancy rapidly raises kynurenic acid levels in mouse placenta and fetal brain. Dev Neurosci 38: 458–468
45. Notarangelo FM, Wons KS, Schwarcz R, (2015) Prenatal LPS exposure preferentially increases kynurenine pathway metabolism in the fetal brain. Soc Neurosci Abstr 40: 74.02
46. Notarangelo FM, Wu HQ, Macherone A. (2012) Gas chromatography/tandem mass spectrometry detection of extracellular kynurenine and related metabolites in normal and lesioned rat brain. Anal Biochem 421: 573–581
47. O’Leary C, Desbonnet L, Clarke N. (2014) Phenotypic effects of maternal immune activation and early postnatal milieu in mice mutant for the schizophrenia risk gene neuregulin-1. Neuroscience 277: 294–305
48. Owen MJ, Sawa A, Mortensen PB, (2016) Schizophrenia. Lancet 388: 86–97
49. Parrott JM, O’Connor JC, (2015) Kynurenine 3-monooxygenase: An influential mediator of neuropathology. Front Psychiatry 6: 116
50. Parrott JM, Redus L, Santana-Coelho. (2016) Neurotoxic kynurenine metabolism is increased in the dorsal hippocampus and drives distinct depressive behaviors during inflammation. Transl Psychiatry 6: e918
51. Pershing ML, Bortz DM, Pocivavsek A. (2015) Elevated levels of kynurenic acid during gestation produce neurochemical, morphological, and cognitive deficits in adulthood: Implications for schizophrenia. Neuropharmacology 90: 33–41
52. Pershing ML, Phenis D, Valentini V. (2016) Prenatal kynurenine exposure in rats: Age-dependent changes in NMDA receptor expression and conditioned fear responding. Psychopharmacology (Berl) 233: 3725–3735
53. Pisar M, Forrest CM, Khalil OS. (2014) Modified neocortical and cerebellar protein expression and morphology in adult rats following prenatal inhibition of the kynurenine pathway. Brain Res 1576: 1–17
54. Pocivavsek A, Notarangelo FM, Wu HQ. (2016) Astrocytes as pharmacological targets in the treatment of schizophrenia: Focus on kynurenic acid. In: Mikhail VP, John LW, (eds) Handbook of Behavioral Neuroscience. Vol. 23. San Diego, CA: Elsevier, pp. 423–443
55. Pocivavsek A, Thomas MA, Elmer GI. (2014) Continuous kynurenine administration during the prenatal period, but not during adolescence, causes learning and memory deficits in adult rats. Psychopharmacology (Berl) 231: 2799–2809
56. Pocivavsek A, Wu HQ, Elmer GI. (2012) Pre- and postnatal exposure to kynurenine causes cognitive deficits in adulthood. Eur J Neurosci 35: 1605–1612
57. Röver S, Cesura AM, Huguenin P. (1997) Synthesis and biochemical evaluation of N- (4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase. J Med Chem 40: 4378–4385
58. Sathyasaikumar KV, Stachowski EK, Wonodi I. (2011) Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr Bull 37: 1147–1156
59. Scharfman HE, Goodman JH, (1998) Effects of central and peripheral administration of kynurenic acid on hippocampal evoked responses in vivo and in vitro. Neuroscience 86: 751–764
60. Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014) Biological insights from 108 schizophrenia-associated genetic loci. Nature 511: 421–427
61. Schwarcz R, Rassoulpour A, Wu HQ. (2001) Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 50: 521–530
62. Seidman LJ, Buka SL, Goldstein JM. (2000) The relationship of prenatal and perinatal complications to cognitive functioning at age 7 in the New England Cohorts of the National Collaborative Perinatal Project. Schizophr Bull 26: 309–321
63. Shepard PD, Joy B, Clerkin L. (2003) Micromolar brain levels of kynurenic acid are associated with a disruption of auditory sensory gating in the rat. Neuropsychopharmacology 28: 1454–1462
64. Stolp H, Neuhaus A, Sundramoorthi R. (2012) The long and the short of it: Gene and environment interactions during early cortical development and consequences for long-term neurological disease. Front Psychiatry 3: 50
65. Swartz KJ, During MJ, Freese A. (1990) Cerebral synthesis and release of kynurenic acid: An endogenous antagonist of excitatory amino acid receptors. J Neurosci 10: 2965–2973
66. Tashiro T, Murakami Y, Mouri A. (2017) Kynurenine 3-monooxygenase is implicated in antidepressants-responsive depressive-like behaviors and monoaminergic dysfunctions. Behav Brain Res 317: 279–285
67. Walker DW, Curtis B, Lacey B.. (1999) Kynurenic acid in brain and cerebrospinal fluid of fetal, newborn, and adult sheep and effects of placental embolization. Pediatr Res 45: 820–826
68. Williams M, Zhang Z, Nance E. (2017) Maternal inflammation results in altered tryptophan metabolism in rabbit placenta and fetal brain. Dev Neurosci 39: 399–412
69. Wonodi I, Stine OC, Sathyasaikumar KV. (2011) Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Arch Gen Psychiatry 68: 665–674
70. Zupan B, Toth M, (2008) Wild-type male offspring of fmr-1+/− mothers exhibit characteristics of the fragile X phenotype. Neuropsychopharmacology. 33: 2667–2675